Aromatic-Cationic Peptides for Post-MI Left Ventricular Remodeling
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Following myocardial infarction, left ventricular remodeling leads to ventricle dilation and heart failure, increasing oxygen demand and being a strong predictor of death, with existing treatments being inadequate.
Innovation Solution
Administration of therapeutically effective amounts of aromatic-cationic peptides, such as D-Arg-2′,6′-Dmt-Lys-Phe-NH2, to stabilize mitochondrial biogenesis and improve cardiac function, potentially combined with cardiovascular agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for left ventricular remodeling, then existing therapy protocols are maintained, but treatment effectiveness is inadequate
Solution Approach 1:
The patent introduces a novel therapeutic parameter by administering aromatic-cationic peptides (such as D-Arg-2′,6′-Dmt-Lys-Phe-NH2) at specific dosages (e.g., 1-10 mg/kg body weight) and timing (within 24-48 hours post-MI), which represents a fundamental change from conventional treatments. This parameter change directly addresses the inadequacy of existing therapies by providing a new mechanism of action that stabilizes mitochondrial biogenesis and prevents LV remodeling.
Solution Approach 2:
The aromatic-cationic peptides act as intermediary substances that mediate between the myocardial infarction event and the pathological remodeling process. These peptides specifically target and stabilize mitochondrial biogenesis in the border zone of infarcted tissue, serving as a molecular mediator that prevents the cascade leading to LV dilation and heart failure, thereby improving treatment effectiveness where conventional therapies fail.
2Productivity
If left ventricle dilation progresses to compensate for reduced stroke volume, then initial compensation occurs, but progressive dilatation eventually leads to congestive heart failure
Solution Approach 1:
The patent applies preliminary action by administering aromatic-cationic peptides within a critical time window (2-48 hours) following myocardial infarction, before progressive dilatation and heart failure develop. This early intervention stabilizes mitochondrial biogenesis in the border zone, preventing the subsequent cascade of pathological remodeling. The preliminary action interrupts the disease progression at its earliest stage, maintaining stroke volume compensation without progressing to failure.
Solution Approach 2:
The aromatic-cationic peptides exert preliminary anti-action by counteracting the pathological remodeling process before it can progress to harmful levels. Specifically, the peptides prevent mitochondrial dysfunction and cellular apoptosis in the border zone, thereby opposing the forces that drive LV dilation and eccentric hypertrophy. This preliminary anti-action maintains productive compensation while preventing the transition to congestive heart failure.
3Reliability
If aromatic-cationic peptides are administered to stabilize mitochondrial biogenesis, then left ventricular function is improved, but the mechanism involves complex mitochondrial and gene expression stabilization
Solution Approach 1:
The patent extracts and targets a specific critical component (mitochondrial biogenesis) within the complex biological system of cardiac remodeling. By focusing therapeutic action on stabilizing mitochondrial DNA and biogenesis processes in the border zone, the invention simplifies the approach to a key target rather than attempting to manage all aspects of the complex remodeling cascade. This extraction of the critical mitochondrial component enables effective LV function improvement despite the overall system complexity.
Data Source
AI summary
The disclosure provides methods of preventing, treating, or ameliorating LV remodeling in a mammalian subject. The methods comprise administering to the subject a therapeutic amount of an aromatic-cationic peptide such as D-Arg-2,6-Dmt-Lys-Phe-NH2.